Cargando…

Baricitinib exposure during pregnancy in rheumatoid arthritis

We here describe the case of a 43-year-old White woman who was diagnosed with rheumatoid arthritis treated with anti-tumour necrosis factor drugs that caused an adverse drug reaction. The objective of this study was to describe the outcome of a pregnancy under baricitinib, a JAK-inhibitor drug, in a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costanzo, Giulia, Firinu, Davide, Losa, Francesca, Deidda, Margherita, Barca, Maria P., Del Giacco, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997965/ https://www.ncbi.nlm.nih.gov/pubmed/32071617 http://dx.doi.org/10.1177/1759720X19899296

Ejemplares similares

Exercise-induced anaphylaxis with an Ayurvedic drug as cofactor: A case report
por: Losa, Francesca, et al.
Publicado: (2019)

Baricitinib for the treatment of rheumatoid arthritis
por: Urits, Ivan, et al.
Publicado: (2020)

Eosinophilic Granulomatosis with Polyangiitis Relapse after COVID-19 Vaccination: A Case Report
por: Costanzo, Giulia, et al.
Publicado: (2021)

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
por: Taylor, Peter C., et al.
Publicado: (2019)

COVID-19: Considerations about immune suppression and biologicals at the time of SARS-CoV-2 pandemic
por: Costanzo, Giulia, et al.
Publicado: (2021)

Right Ventricular Subclinical Dysfunction in SLE Patients Correlates with Metabolomic Fingerprint and Organ Damage
por: Deidda, Martino, et al.
Publicado: (2023)

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Difficult-to-treat rheumatoid arthritis treated with Abatacept combined with Baricitinib: A case report
por: Qi, Jia-Ping, et al.
Publicado: (2023)

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
por: Kawalec, Paweł, et al.
Publicado: (2019)

Are There Any Ethnic Differences in the Response to Baricitinib for the Treatment of Rheumatoid Arthritis?
por: Zahir Hussain, Wajith Hussain, et al.
Publicado: (2021)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience
por: Tesei, Giulia, et al.
Publicado: (2021)

Cofactors, age at onset, allergic comorbidities and gender are different in patients sensitized to omega-5 gliadin and Pru p 3
por: Costanzo, Giulia, et al.
Publicado: (2022)

Impaired Endothelial Function in Hereditary Angioedema During the Symptom-Free Period
por: Firinu, Davide, et al.
Publicado: (2018)

Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis
por: Koumaki, Dimitra, et al.
Publicado: (2019)

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2020)

Baricitinib therapy response in rheumatoid arthritis patients associates to STAT1 phosphorylation in monocytes
por: Tucci, Gloria, et al.
Publicado: (2022)

Dose/Exposure‐Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis
por: Zhang, Xin, et al.
Publicado: (2017)

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
por: Genovese, Mark C, et al.
Publicado: (2018)

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
por: Iwamoto, Naoki, et al.
Publicado: (2021)

Effectiveness of Baricitinib in Refractory Seronegative Rheumatoid Arthritis and Uveitis: A Case Report
por: Kaneko, Yutaka, et al.
Publicado: (2022)

Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis
por: Hernández-Cruz, Blanca, et al.
Publicado: (2023)

Exercise Training, Lymphocyte Subsets and Their Cytokines Production: Experience of an Italian Professional Football Team and Their Impact on Allergy
por: Del Giacco, Stefano R., et al.
Publicado: (2014)

Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis: An Integrated Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2018)

Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2020)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

HLA-C dysregulation as a possible mechanism of immune evasion in SARS-CoV-2 and other RNA-virus infections
por: Loi, Eleonora, et al.
Publicado: (2022)

Immediate Effect of Baricitinib on Arthritis and Biological Disease-Modifying Antirheumatic Drug-Induced Psoriasis-Like Skin Lesions in Two Patients with Rheumatoid Arthritis
por: Tada, Yoshifumi, et al.
Publicado: (2021)

Exercise and asthma: an overview
por: Giacco, Stefano R. Del, et al.
Publicado: (2015)

Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab
por: Ledda, Andrea Giovanni, et al.
Publicado: (2023)

Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2020)

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
por: Schlueter, Max, et al.
Publicado: (2019)

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review
por: Emery, Paul, et al.
Publicado: (2021)

Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
por: Li, SiNi, et al.
Publicado: (2021)

Efficacy and safety of different doses of baricitinib for rheumatoid arthritis: A Bayesian network meta-analysis
por: Haikun, Wang, et al.
Publicado: (2022)

Comparative Effectiveness of First‐Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set
por: Ciciriello, Sabina, et al.
Publicado: (2023)

Top-Down Proteomics of Human Saliva Discloses Significant Variations of the Protein Profile in Patients with Mastocytosis
por: Serrao, Simone, et al.
Publicado: (2020)

Salivary Cystatin D Interactome in Patients with Systemic Mastocytosis: An Exploratory Study
por: Serrao, Simone, et al.
Publicado: (2023)

Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Baricitinib retention rate: ‘real-life’ data from a mono-centric cohort of patients affected by rheumatoid arthritis
por: Baldi, Caterina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dtvcvsm3n8fmlrqmljbt4113t9